Addressing the Innovation “Valley of Death:” It’s the Products, Stupid!

new funding model for innovation, which we call the Distributed Partnering Model. While we explain in our paper how to apply this model to advance life sciences innovation, it can also be applied to high-tech, cleantech, and other technology sectors.

This model emphasizes the importance of advancing the innovative technologies and products— instead of a model that emphasizes building individual companies around each new discovery or invention. In our model, we have identified four independent entities that work collectively to advance innovation—based on the unique assets, skill sets, cultures, and risk tolerance to be applied. Each would have a rational investment risk and reward as a specific innovation gets relayed from one business entity to the next. They are:

Discovery: A research institute that focuses on new discoveries.

Definition: A company that invests in defining the initial product(s) from the research-based discoveries in a given field of expertise.

Development: A company with responsibility for funding and advancing product development.

Delivery: A company with a significant marketing and distribution channel.

Our model is fundamentally different than previous models in that it focuses on these independent groups to collectively contribute to advancing products from research discovery to commercialization. As senior fellow Frank Douglas says in a statement issued by the Kauffman Foundation, “The model focuses on advancing products as opposed to companies. We need thousands of new products, not thousands of new companies.”

There are two key enabling elements of the proposed model: the formation of a new type of company to address the “Valley of Death” bottleneck, called a product definition company (PDC), and a more efficient use of infrastructure and product development expertise provided by professional service providers (PSP). PDCs would focus on translating a portfolio of research discoveries into an early, development stage product. These would be managed by an experienced entrepreneurial team with significant operating experience in a given field. The PDC business model would call for SELLING the product or technology assets to VCs or distribution companies after the initial product definition phase for further product development and, eventually, delivery to the market by distribution companies. Potential PDC investors would include angels, large corporations, VCs, foundations, etc., and investor focus would be on their field of interest and the expertise of the operating team.

Instead of investing in infrastructure, as was the norm for the VC start-up company model, the translational experiments to reach “proof of relevancy” would be contracted to PSPs to perform the key development activities. In this model the PSPs would become a significant force for providing expertise in a given area. Furthermore, by transferring the product development (and technology) to the PSPs, acquirers will not be dependent on the PDC management team for expertise (with perhaps the exception of the project manger). Following acquisition, the product development company could operate in a

Author: Duane J. Roth

In Memoriam: Our friend and Xconomist Duane Roth passed away on August 3, 2013, after a bicycle accident. We at Xconomy are deeply saddened by his loss. Duane J. Roth was Chief Executive Officer and member of the Board of CONNECT. CONNECT is the globally recognized public benefits organization fostering entrepreneurship in the San Diego region by catalyzing, accelerating, and supporting the growth of the most promising technology and life sciences innovation. Focused on assisting start-up companies in the San Diego region, CONNECT has been directly involved with over 1,500 companies since its inception in 1985. Prior to joining CONNECT, Mr. Roth founded Alliance Pharmaceutical Corp., where he served as Chief Executive Officer and Chairman of the Board. Prior to Alliance, Mr. Roth held senior management positions at Johnson & Johnson and Wyeth operating companies. He served as a member of the Board of Directors and executive committees of the Biotechnology Industry Organization (BIO), the California Healthcare Institute (CHI), BIOCOM (past Chair), Deep Sky Software Inc., and SAIC-Frederick, Inc. National Cancer Institute. Mr. Roth served on a number of advisory committees and boards of the University of California, including the President’s Board on Science and Innovation, the UCSD Sulpizio Cardiovascular Center (past Chair), the UCSD Skaggs School of Pharmacy and Pharmaceutical Sciences, the Preuss Charter School (Chair), California Institute for Telecommunications and Information Technology (Calit2), the UC San Diego Foundation Board (past Chair), and UCSD Health Sciences Advisory Board. Mr. Roth was active in the San Diego community, serving on the board of the San Diego Regional Economic Development Corporation (past Chair), the San Diego Regional Chamber of Commerce, the Lincoln Club of San Diego (past Chair), the San Diego State University College of Business (past Chair), San Diego State University Sciences & Engineering Dean’s Advisory Board, as co-Chair of the Regional Housing Working Group, and a member of the Advisory Council for Math for America. Mr. Roth also served as a member of the Executive Board for the California State University (CSU) Professional Science Master’s (PSM) Programs. Mr. Roth was appointed to the Independent Citizens Oversight Committee for the California Institute of Regenerative Medicine (CIRM) by Governor Arnold Schwarzenegger and he also served as a member on the Governor’s Commission for Jobs and Economic Growth. Mr. Roth was a graduate of Iowa Wesleyan College, where he served as a trustee.